Bell Brain Function Capsules
Bell Brain Function Capsules, licence 80042656: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Bell Lifestyle Products Inc.
- NPN or DIN-HM
- 80042656
- Status
- Active licence
- Licence date
- 5 June 2013
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Information
Vitamine B12: the published amount (330 mg) is more than a thousand times the maximum supplement dose: this is very likely a unit error in the source. No dose comparison is made for this nutrient.
contrôle de vraisemblance. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Huperzia serrata Source : Feuille Potency : 1.0 % Huperzine A | 0.025 mg | Not calculated |
| Ginkgo biloba Source : Feuille Extraction ratio : 15:1 Dry plant equivalent : 1500 mg Potency : 24.0 % Flavone glycosides | 100.0 mg | Not calculated |
| Ginkgo biloba Source : Feuille Potency : 6.0 % Terpene Lactones | Not specified | Not calculated |
| Vitamine B12 Source : Méthylcobalamine | 330.0 mg | 990,000 µg |
| Lécithine Source : Glycine max - Graine | 100.0 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Gélatine, Dioxyde de silicium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 1.0 Capsule | 3.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to enhance cognitive function in adults. Helps to enhance memory in adults. Helps to prevent folate deficiency.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80042656
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.